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Objectives: This study investigated the impact of a combined intervention strategy to improve antimi-
crobial prescribing at University Hospital Groningen. For the intervention, the antimicrobial treatment
guidelines were updated and disseminated in paperback and electronic format. The credibility of the
guidelines was improved by consultation with users. In a second phase, academic detailing (AD) was
used to improve speciﬁc areas of low compliance with the guidelines.
Materials and methods: Prescribing data were prospectively collected for 2869 patients receiving 7471
prescriptions for an antimicrobial for an infection covered by the guidelines between July 2001 and
September 2003. After collection of baseline data, the guidelines were actively disseminated in
February 2002. Next, after a 5 month interval, a second intervention, i.e. an AD approach, addressed
suboptimal prescribing of ciproﬂoxacin and co-amoxiclav. Segmented regression analysis was used to
analyse the interrupted time-series data.
Results: At baseline, compliance with the drug choice guidelines was 67%. The ﬁrst intervention
showed a signiﬁcant change in the level of compliance of 115.5% (95% CI: 8%; 23%). AD did not lead
to statistically signiﬁcant additional changes in already high levels 112.5% (95% CI:–3%; 28%) of
compliance. Post-intervention compliance was stable at 86%.
Conclusions: Updating the guidelines in close collaboration with the specialists involved followed by
active dissemination proved to be an efﬁcient way to improve compliance with guideline recommen-
dations. An 86% compliance level was achieved in this study without compulsory measures. A ceiling
effect may have limited the added value of AD.
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Introduction
Various studies have shown that inappropriate antimicrobial use
is common in the community as well as in hospital care. Impru-
dent antimicrobial use has contributed to the emergence and
spread of drug-resistant microorganisms, and increased treatment
costs.
1–3 To curb this inappropriate use, guidelines on antimicro-
bial therapy have been developed but compliance with their
recommendations has only been moderate.
4,5 Various strategies
have been used to implement these guidelines in clinical practice
and strengthen antimicrobial control programmes, with mixed
results.
1,6–9 Success is increased when targeting the intervention
at existing barriers to following guideline recommendations.
10 In
2001, we interviewed specialists and resident physicians (resi-
dents) to elicit barriers in the hospital to following antibiotic
guidelines in order to select an appropriate strategy to improve
antimicrobial prescribing. We have shown that the existing
guidelines were not credible for the targeted physicians.
11 They
felt insufﬁciently involved in the development of the guidelines
and considered the guidelines outdated and not well distributed
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residents are not independent decision-makers in a teaching
hospital setting.
11
A strategy that has proved to be effective in improving anti-
biotic use in a hospital setting is the one-on-one educational
programme (‘academic detailing’).
6 However, most studies use
multifaceted approaches to optimize antimicrobial use, combin-
ing educational approaches, formulary restriction, intravenous to
oral switch protocols, involving antimicrobial management
teams, and critical pathways.
3,12,13 In the majority of these inter-
vention studies, antimicrobial treatment guidelines were distribu-
ted before a speciﬁc intervention.
Recently, however, it has been disputed that combined
interventions are always more effective.
10 The rigorousness of
various intervention studies aimed at optimizing antimicrobial
use has been criticized.
9 Many studies did not allow ﬁrm
conclusions. These ﬁndings led us to develop a two-phase inter-
vention strategy whose separate phases were analysed individu-
ally. In the ﬁrst phase, a relatively simple intervention was
carried out, i.e. improving the accessibility of updated, more
credible guidelines that had been developed after intensive
consultation rounds with the targeted physicians. This interven-
tion was followed by academic detailing sessions focusing on
speciﬁc areas of low compliance with guideline recommen-
dations and addressing both residents and specialists.
The aim of this study was to assess the impact of a two-phase
intervention, i.e. on prescribing compliance with the antimicro-
bial treatment guideline recommendations and on drug costs.
Furthermore, we studied the additional impact of academic
detailing on compliant prescribing by the speciﬁcally targeted
physicians for the selected clinical problem.
Materials and methods
The analysis of this study was carried out in two steps. First, the
overall impact on compliance with the guidelines and antimicrobial
drug costs was analysed. In a second step, the additional impact of
the second intervention, academic detailing, was analysed.
Study population and study design
Patients treated with an antimicrobial agent were prospectively
followed-up after admission to one of the following sub-departments
of the 190 bed Department of Internal Medicine: pulmonology,
haematology, nephrology, gastroenterology, general internal medi-
cine and the intensive care unit. The study ran from July 2001 until
July 2003 in University Hospital Groningen. The hospital serves as
a tertiary care facility for the north-eastern part of the Netherlands,
but also renders second-line care to the city of Groningen and its
surrounding towns. Every year, about 5000 patients are admitted to
the Department of Internal Medicine, with an average stay of 11
days. Sporadic cases of MRSA, VRE, penicillin non-susceptible
pneumococci, and Enterobacteriaceae producing beta-lactamase are
observed, comprising less than 1% of the blood culture isolates.
Bacterial resistance patterns are generally comparable with those in
the Netherlands,
14 consequently empirical therapy is not targeted at
such pathogens with reduced antibacterial sensitivity.
The study was set up as an interrupted time-series (ITS). This
study design is characterized by a series of measurements over time
that are interrupted by an event, i.e. intervention. Baseline data were
collected over 7.5 months, and the revised guidelines were intro-
duced with a 5 month follow-up (Figure 1). Academic detailing
sessions took place for 5 months and ﬁnally data were collected
9 months post-intervention. Data were extracted from paper medical
records, nursing ﬁles, drug administration charts and from the com-
puterized hospital information system. The principal clinical diagno-
sis of the treating physician at the time of prescribing was compared
with guideline recommended therapy. Additionally, data were col-
lected to support accurate assessment of prescribed antimicrobial
therapy, e.g. inﬂammation parameters, Gram’s stain, culture and
antimicrobial sensitivity. Patient data collected included age, sex,
co-morbidity, known allergic reactions to antimicrobial agents, pre-
vious antimicrobial use and anamnesis. Prescription data encom-
passed drug choice, duration of therapy, dosage and administration
route.
Intervention
The two separate phases of the two-phase intervention are discussed
below in more detail.
Revised guidelines. The 1999 hospital treatment guidelines for anti-
microbial therapy were revised. The recommendations were adapted
to incorporate recent (international) evidence, national guidelines
and local antimicrobial resistance patterns. Intensive consultation
rounds were held with specialists and the hospital antimicrobial
committee to ﬁne-tune the hospital guidelines with formal depart-
mental policies and national guidelines. The revised guidelines were
introduced to the Department of Internal Medicine in two specially
organized sessions for the daily clinical reports, where feedback on
antimicrobial use patterns aggregated at the departmental level was
given. The guidelines (see the Appendix), were handed over in
paperback format to all physicians. An electronic, well-indexed and
searchable version was made available on the hospital intranet.
Academic detailing. In the second intervention period, physicians
were approached with the explicit message to prescribe more in line
with the revised guideline recommendations for speciﬁc clinical pro-
blems using actual examples. The sessions targeted physicians from
the departments of general internal medicine, haematology, gastroin-
testinal diseases and nephrology. The sessions comprised individual
and group educational interactive sessions, with additional use of
aggregated feedback material on antimicrobial prescribing.
6,15 Super-
vising board certiﬁed specialists were individually approached. Pre-
certiﬁcation residents were initially approached as a group during
two regular resident meetings, and individually within 1 day of pre-
scribing ciproﬂoxacin or co-amoxiclav not compliant with guideline
recommendations. The sessions focused on the use of ciproﬂoxacin
Figure 1. Time frame of intervention study.
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551and co-amoxiclav as these antibiotics comprised 30% of all antimi-
crobial agents prescribed during baseline and were frequently not
prescribed in line with guideline recommendations (Table 1). The
sessions addressed the limited guideline recommended use of these
antibiotics. It was stressed that ciproﬂoxacin was not prescribed in
compliance with the guidelines in 130 (71%) of the 183 prescrip-
tions. In particular, co-amoxiclav was not prescribed in compliance
for culture-targeted therapy, 38 (62%) out of 61 prescriptions,
mainly caused by a failure to streamline to a narrower spectrum
agent. The increasing bacterial resistance to ciproﬂoxacin in the hos-
pital was shown as well as the observed equal in vitro efﬁcacy in
our hospital of guideline drugs compared with ciproﬂoxacin and co-
amoxiclav for empirical antimicrobial therapy. The three key mess-
ages were (i) the importance of streamlining therapy based on
in vitro bacterial sensitivity, (ii) the efﬁcacy of the guideline agents,
and (iii) the importance of preventing the development of bacterial
resistance. One-on-one sessions with residents triggered by treat-
ment decisions not in line with the guidelines repeated this general
message focusing on the case at hand, i.e. individual feedback.
Outcome measures
The primary outcome measure was deﬁned as (mean) compliance of
prescribed antimicrobial therapy to the updated guidelines. Of a
total of 8530 prescriptions, 246 (2.9%) were excluded from the ana-
lysis because of a lack of sufﬁcient data and 813 (9.6%) because of
an indication not included in the guidelines. An independent phar-
macist-observer assessed each prescription for compliance with the
guideline recommended drug, taking the relevant case characteristics
into consideration. An algorithm designed by Kunin et al. and
adapted by Gyssens et al. was used to aid systematic assessment of
antimicrobial therapy.
16,17 Where appropriate, prescriptions were
assessed according to explicit guideline recommendations for
speciﬁc infections (empirical therapy) or cultured pathogens
(culture-targeted therapy). If an isolated pathogen was resistant to
the guideline recommended agent or a patient had previous hyper-
sensitivity to a recommended agent, then this overruled these rec-
ommendations. The narrowest spectrum drug effective against the
isolated pathogen was considered the drug of choice, i.e. compliant.
In the event of documented hypersensitivity, compliance with the
guidelines was assessed on implicit guideline criteria to prescribe
the narrowest spectrum antibiotic that adequately covers expected or
isolated pathogens. In a pilot study, the reliability of the assessment
proved to be good; four pharmacists and physicians were in good
agreement (overall kappa 0.72) for drug choice.
18 Compliance was
calculated for all empirical and culture-targeted therapy plus pro-
phylaxis combined.
The secondary outcome measure was the antimicrobial drug
costs in Euros (e) per 100 days of hospital stay for patients on anti-
microbial therapy. Drug costs were calculated based on the hospital
pharmacies’ drug acquisition costs, indexed at the April 2001 prices.
The primary and secondary outcome measures were assigned to
2 week periods (see analysis) during which the antimicrobial
therapy was initiated. The day of admittance decided to which study
period a patient’s length of stay was ascribed.
Table 1. Study characteristics
Baseline In-between Academic detailing Post-intervention P value
Period 1 July 2001–
15 January 2002
1 March 2002–
31 July 2002
1 August 2002–
31 December 2002
1 January 2003–
30 September 2003
Months 7.5 5 5 9
Overall study population characteristics
Data points (2 weeks) 15 10 10 18
% AB users in Dept. of Internal Medicine 43% (S.D. 5%) 47% (S.D. 2%) 50% (S.D. 2%) 52% (S.D. 3%) 0.01
a
Antimicrobial users, n=2869 697 549 601 1022
Female (%) 304 (44%) 258 (47%) 288 (48%) 485 (48%) 0.36
a
Died (%) 69 (10%) 43 (8%) 68 (11%) 71 (7%) 0.01
a
Length of stay (days)
b 17 (9–29) 16 (8–28) 15 (8–28) 15 (9–26) 0.20
c
Age (years)
b 59 (47–71) 61 (48–73) 60 (44–71) 59 (45–72) 0.37
c
Prescriptions (Rx)
d, n=7471 1714 1437 1599 2721
Ciproﬂoxacin (%) 183 (11%) 124 (8.6%) 146 (9.1%) 272 (10%) 0.20
a
Co-amoxiclav (%) 311 (18%) 323 (23%) 294 (18%) 524 (19%) 0.009
a
Rx per data point 114 (S.D. 27) 143 (S.D. 34) 160 (S.D. 14) 151 (S.D. 32) 0.001
a
Academic detailing subpopulation characteristics
Data points (1month) 7 5 5 9
Antimicrobial users, n=1740 392 322 369 657
Female (%) 186 (47%) 173 (54%) 187 (51%) 330 (50%) 0.42
a
Died (%) 25 (6.4%) 24 (7.5%) 36 (9.8%) 32 (4.9%) 0.03
a
Length of stay (days)
b 18 (10–30) 18 (9–31) 16 (8–31) 17 (9–28) 0.10
c
Age (years)
b 58 (47–70) 58 (47–73) 59 (45–72) 57 (43–71) 0.32
c
Prescriptions (Rx), n=4465 846 874 961 1784
Ciproﬂoxacin + co-amoxiclav (%) 187 (22%) 220 (25%) 227 (24%) 453 (25%) 0.27
a
Other antimicrobials 659 654 734 1331
Rx per data point 30 (S.D. 6) 44 (S.D. 13) 45 (S.D. 6) 50 (S.D. 16) 0.02
a
aANOVA.
bMedian and interquartile range.
cKruskal–Wallis.
dRx: prescription.
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introduction of the guidelines was restricted to the use of ciproﬂoxa-
cin and co-amoxiclav and targeted physicians. Compliance for the
smaller number of prescriptions for ciproﬂoxacin and co-amoxiclav
was aggregated per month rather than per 2 weeks to increase the
reliability of the estimate. The level of compliance for the other pre-
scribed antimicrobial agents served as a non-equivalent outcome
measure or control group, providing additional evidence of a causal
relationship between intervention and outcome. An intervention tar-
geted at optimizing the prescribing of ciproﬂoxacin and co-amoxi-
clav was expected to have no impact on compliance with the
guidelines for other prescribed antimicrobial agents.
19
Statistical analysis
Study characteristics are described for the different study periods,
using ANOVA and Kruskal–Wallis where appropriate (Table 1).
Segmented linear regression analysis was used to assess the level
and trend of compliance with the guidelines and drug costs at base-
line and how much the interventions changed these levels: after
each intervention phase and the trend over time. The time-series
data were interrupted by the two interventions: introduction of the
updated guidelines (February 2002) and 5 months of academic
detailing, which were left out of the analysis. Durbin–Watson stat-
istics and (partial) autocorrelation functions were used to check for
possible autocorrelation.
20 If trends in compliance or costs turned
out to be non-signiﬁcant, a more parsimonious statistical analysis of
mean compliance pre- and post-intervention with a Student’s t-test
was also carried out.
20 Overall impact on compliance and drug costs
of the two-phased intervention was analysed for the combined
impact of the two phases in the segmented linear regression analy-
sis. The study design meets the criteria for a robust ITS, that is
more than three data points—in our study, between 10 and 18—
each consisting of at least 30 prescriptions.
21
Results
Overall effect
During the total study period, the percentage of patients receiv-
ing antimicrobial agents in the Department of Internal Medicine
increased from 43% to 52%. A total of 7471 antimicrobial pre-
scriptions for 2869 patients were assessed for compliance with
the guidelines. The number of prescriptions per 2 week period
during baseline was 114 (S.D. 27), which increased to 143–160
prescriptions in later study periods (Table 1). Patients’ median
age was 60 with a small majority being male. The median length
of hospital stay was 16 days, compared with 11 days for all
patients admitted to the study departments. This longer duration
of stay is most likely caused by the case mix, which included
solid-organ transplant and haematology patients whose disease
course was aggravated by an infection. Such long admissions
may not be uncommon for patients with infectious diseases and
is observed elsewhere.
22 The overall mortality averaged 7–11%.
Infection-related mortality was not identiﬁed separately.
Compliance with guideline recommendations
Antimicrobial therapy followed the revised guideline rec-
ommended drug choice in 67% of cases in the segmented linear
regression analysis at baseline (Figure 2). No signiﬁcant trend in
compliance with the guidelines over time was observed during
the baseline period, +0.14% (95% CI: 0.4%; 0.7%). Introduc-
tion of the revised guidelines led to a signiﬁcant immediate
increase in compliance of +15.5% (95% CI: 8%; 23%, P<0.001)
but no signiﬁcant change in trend 0.69% (95% CI: 1.8%;
0.4%). Academic detailing sessions did not lead to further sig-
niﬁcant increases in level of compliance, 12.5% (95% CI: 3%;
28%) or a change in trend, +0.54% (95% CI; 0.5%; 1.6%).
Durbin–Watson statistics and inspection of residuals over time
did not indicate signiﬁcant autocorrelation.
The more parsimonious analysis, Student’s t-test, showed sig-
niﬁcant (P<0.001) differences in compliance between baseline
(68%), in-between (81%), and post-intervention periods (86%)
[a 1% difference in level of compliance at baseline (67% versus
68%) is caused by the different aggregation level for calculating
mean compliance. Compliance in the regression analysis is cal-
culated based on the mean compliance per 2 weeks; in the parsi-
monious analysis, mean compliance is calculated per time
period, i.e. mean compliance at baseline, in-between and post-
intervention periods].
Almost 90% (6608/7417) of all antimicrobial agents were
prescribed for seven infections (Figure 3). After the ﬁrst inter-
vention, compliance improved signiﬁcantly for all but two major
infections. The second intervention, comparing in-between and
post-intervention periods, did not show additional improvement
in compliance, except for non-targeted ear, nose and throat
infections in the Department of Internal Medicine.
Drug costs
Antimicrobial drug costs per 100 bed days for patients on anti-
microbial therapy plotted per 2 weeks showed a very irregular
pattern during the whole study period (Figure 4). In the segmen-
ted regression analysis four outliers, deviating >2 S.D.s from the
mean, were excluded from the model. These values were caused
by a few patients who were prescribed extremely expensive anti-
microbial therapies, e.g. amphotericin encapsulated in liposomes.
At baseline, the level of antimicrobial drug costs was e1548 per
100 bed days for antimicrobial users, with a non-signiﬁcant
Figure 2. Percentage compliance with antibiotic guidelines, 1 July 2001–30
September 2003.
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553trend, +e1.3 (95% CI: e52; e54). After the introduction of the
revised guidelines, there was a non-signiﬁcant drop in the level
of drug costs of e151 (95% CI: e960; e658), and a non-signiﬁ-
cant change in trend, e19 (95% CI: e133; e96). After aca-
demic detailing, a non-signiﬁcant increased level of drug costs
of e411 (95% CI: e1108; e1929) and a non-signiﬁcant change
in trend +e42 (95% CI: e67; e152) were observed.
Because of the lack of signiﬁcant trend in drug costs in any
segment of the study, the impact of the intervention on drug
costs was analysed with an independent t-test. Again, no signiﬁ-
cant changes were observed (data not shown).
Academic detailing
In the four internal medicine departments targeted in the aca-
demic detailing sessions, 1740 patients received 4465 antimicro-
bial prescriptions (Table 1). Main characteristics were similar
for the case mix of the subpopulation with the overall study
population. At baseline, 30 (S.D. 6) prescriptions for ciproﬂoxa-
cin and co-amoxiclav were assessed per month, increasing to 50
prescriptions per month in the post-intervention period.
The level of compliance with the guideline recommended use
of ciproﬂoxacin and co-amoxiclav was 42% at baseline with a
non-signiﬁcant trend of 0.5% (95% CI: 4.2%; 3.1%) per
month in the segmented linear regression analysis (Figure 5).
Compliance signiﬁcantly increased by 37.8% (95% CI: 12%;
64%) after the ﬁrst intervention, but with a non-signiﬁcant
additional decline in trend 1.5% (95% CI: 8.6%; 5.6%). No
signiﬁcant change in level +28% (95% CI: 18%; 74%), and
trend +1.2% (95% CI: 5.4%; 7.8%) in compliance was obs-
erved after academic detailing. No autocorrelation was observed.
The independent Student’s t-test showed that mean compli-
ance was 40% in the baseline period, 70% in the in-between
period, and 79% in the post-intervention period [again a small
difference in compliance at baseline is observed in the two analy-
sis methods (42% versus 40%), caused by the aggregation level,
i.e. either per month or per study period]. The 30% increase after
the ﬁrst intervention and the 9% difference in in-between and
post-intervention periods were signiﬁcant (P<0.001).
At baseline, a clear difference was observed between compli-
ant prescribing of ciproﬂoxacin and co-amoxiclav versus that of
all other antimicrobial agents (Figure 5). The combined interven-
Figure 3. Compliance with guideline recommendations for infectious dis-
eases in the different study periods.
Figure 4. Drug costs (e) for antimicrobial agents per 100 bed-days for anti-
microbial users in the Department of Internal Medicine, 1 July 2001–30 Sep-
tember 2003.
Figure 5. Compliance with antibiotic guidelines at selected subdivisions of
the Department of Internal Medicine, 1 July 2001–30 September 2003.
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pronounced impact on the two targeted antibiotics than on the
other drugs prescribed.
Discussion
This study showed that revised guidelines can lead to clear
improvements in compliance with the recommendations when
actively disseminated and when ‘ownership’ is increased by
ﬁne-tuning the recommendations with departmental drug policies
in consultation with ‘targeted’ physicians. A sense of ownership
of the guidelines, as also described elsewhere, increased the
credibility of the guideline recommendations for the phys-
ician.
23,24 We think this played an important role in the adoption
and implementation of the guidelines as a whole. Compliance
was increased for most infections covered by the guidelines,
whereas simple distribution of written guidelines, but without
special attention to their acceptance, had at best a limited impact
on physicians’ prescribing behaviour.
25
Baseline compliance, limited to those indications covered by
the guidelines, was relatively high (67%), higher than the reported
40–60% in the literature.
4,5 This may have been caused by
limiting this study to drug choice instead of also including therapy
duration, dosage and administration route.
26 The limitation to
drug choice as an assessment criterion of therapy was chosen
because it turned out to be more reliable than these other aspects
in our pilot study looking at the reliability of the assessment.
Clearly, following guideline recommendations does not
always imply that costs will decrease. Cost savings documented
in other studies aimed at improving antimicrobial use could not
be reproduced.
12 In other studies, cost savings have often been
achieved, for example in switch protocols, where intravenous
therapy was changed to oral therapy at an early stage,
27 or
through computerized support.
28
During the study, apart from increased compliance, we
observe an increasing percentage of patients admitted to the
Department of Internal Medicine being treated with an
antimicrobial. It is possible that increased attention to
antimicrobial policy and guidelines led physicians to prescribe
antimicrobials with less reserve. Nevertheless, this increased use
was in line with guideline recommendations. Furthermore, the
volume of antimicrobials prescribed with an indication not
covered by the guideline recommendations did not increase
during the study. Antibiotics were thus not increasingly
prescribed for possible non-valid indications, even more so
because, of the 813 prescriptions excluded for non-guideline
covered indications, 382 (47%) were for indications that will be
covered by a future edition of the guidelines.
The additional impact of academic detailing was limited,
despite consistent positive ﬁndings in the literature.
1,6 In our
study, we observed only a small impact on prescribing beha-
viour. This limited impact was possibly caused by a ceiling
effect. Apparently, we had already achieved nearly optimal anti-
microbial prescribing. No clinical guidelines will be speciﬁc
enough for all patients under all circumstances. A need to devi-
ate from guideline recommendations for clinical reasons
will always remain.
29 Only four individual academic detailing
sessions were triggered by non-compliant prescribing of cipro-
ﬂoxacin and co-amoxiclav. Many of the non-compliant prescript-
ions had been changed or discontinued by the moment of
detection.
The revised antibiotic guidelines resulted in improved compli-
ance, especially in the ﬁrst 6 weeks after introduction. Visual
interpretation of the data indicated a gradual increase in compli-
ance during the academic detailing period for the two targeted
antibiotics. This trend does not seem to exist for other prescribed
antimicrobial agents. Academic detailing may have halted a
possible lapse in compliance after the ﬁrst intervention.
An ongoing system of reminders might therefore be necessary to
maintain a high level of compliance.
A limitation to estimating the true impact of academic detail-
ing was the relatively small number of prescriptions per month
and the limited number of months in the in-between period. This
led to a relatively large variation in mean compliance per month
and uncertainty in the calculated regression line, reducing the
power of the study to detect a difference in compliance levels.
In this study, we tried to limit a number of intrinsic threats to
the validity of the interrupted time-series design.
19,20 To protect
against underlying secular trends, no other antimicrobial policy
activities were simultaneously initiated in the hospital. A seaso-
nal effect on compliance with the guidelines seemed unlikely
based on 5 years of pharmacy supply data to the Department of
Internal Medicine (data not shown). A sufﬁciently large number
of data points before and after the interventions guaranteed a
reliable statistical analysis. The primary outcome measure was
reliable, showing good agreement on assessment of drug choice
by hospital pharmacists and internists.
The impact of improved prescribing quality, i.e. more compli-
ance with the guidelines on infection-related mortality was not
assessed in this study. In general, no effect was observed on
overall mortality and length of stay. Further research into level
of compliance with guideline recommendations and the impact
on bacterial resistance and infection-related mortality is needed
to support the assumption that optimal antimicrobial use leads to
better quality of care.
Our approach has revealed a clinically relevant, more rational
selection of antimicrobial agents optimally targeting expected
and isolated pathogens in our hospital setting. Thus, the active
introduction of revised guidelines is a relatively simple method
to ensure high levels of compliance. Academic detailing may
support high levels of prescribing quality, but before a labour-
intensive intervention to increase compliance with guideline rec-
ommendations is considered, it should be investigated whether
those guidelines are sufﬁciently credible to the target group.
The lesson learned was that attention to guidelines worked.
Increased ownership and ensuring easy access to the information
are important but well-known elements in the process of adop-
tion and implementation of guidelines.
23 The challenge will be
the continuation of the process of bringing the guidelines to
notice. This may involve academic detailing or less labour-inten-
sive methods such as computerized decision support.
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Appendix: Hospital Guidelines, University Hospital
Groningen
The guidelines consist of 17 chapters on antimicrobial therapy
and eight chapters on antimicrobial prophylaxis. Additional
chapters give recommendations on antimicrobial use during
pregnancy and while breastfeeding, for renal and hepatic
impaired patients, and antibacterial sensitivity patterns of iso-
lated pathogens in the hospital. The guidelines also give general
recommendations on when and how to take appropriate bacterial
culture samples, and streamline therapy. Literature references
are provided on which the guideline recommendations are based.
As an example, guideline recommended agents for empirical
therapy are given below for the three most common types of
infection. The guidelines also provide recommendations for dos-
ing, administration route, and duration of therapy (not shown) .
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556Type of infection Recommend drug choice
Urinary tract infection (UTI)
lower UTI
uncomplicated nitrofurantoin, trimethoprim (or norﬂoxacin)
male co-trimoxazole
catheter in situ (+fever) amoxicillin+tobramycin
acute pyelonephritis cefuroxime plus tobramycin, or ciproﬂoxacin
Sepsis
urosepsis, no catheter cefuroxime or tobramycin
urosepsis, catheter in situ amoxicillin+(ciproﬂoxacin or tobramycin)
hospital-acquired pneumonia cefuroxime+tobramycin
abdominal, unknown location amoxicillin+tobramycin+metronidazole
abdominal, bile duct piperacillin+tobramycin
Lower respiratory tract infections
community-acquired pneumonia
suspected Legionella)
co-amoxiclav (+erythromycin)
hospital-acquired pneumonia,
severe or with additional risk factors
cefuroxime+tobramycin, or ceftazidime
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